Form 4: United Therapeutics Executive Exercises Share Tracking Awards

Paul A. Mahon, EVP & General Counsel at United Therapeutics, executed a pre-arranged transaction involving share tracking awards, resulting in a change in his beneficial ownership.

Summary

• Paul A. Mahon, an executive at United Therapeutics, exercised 7,700 share tracking awards on December 19, 2024.
• These awards were exercised at a price of $163.30 per share.
• The transaction was part of a pre-arranged 10b5-1 plan established on June 20, 2024.
• Following the transaction, Mr. Mahon's direct holdings of common stock decreased by 7,700 shares.
• The share tracking awards are non-dilutive cash-settled stock appreciation rights, which can only be settled in cash and not converted into common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment. It is a standard regulatory filing.

Industry Context

This transaction is a routine execution of a pre-arranged trading plan by a company executive, which is common practice to avoid accusations of insider trading. It reflects standard executive compensation practices within the biotech industry.

Comparison to Industry Standards

• The use of share tracking awards is a common method of executive compensation in the biotech industry, similar to stock options or restricted stock units.
• Many companies, such as Amgen, Gilead Sciences, and Biogen, use similar equity-based compensation plans for their executives.
• The 10b5-1 trading plan is a standard practice to allow insiders to trade company stock without violating insider trading laws, and is widely used across the industry.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as the share tracking awards are cash-settled and non-dilutive.

Key Dates

Keywords

share tracking awards, insider trading, 10b5-1 plan, executive compensation, stock appreciation rights, United Therapeutics, UTHR